IL262482A - New polypeptides - Google Patents

New polypeptides

Info

Publication number
IL262482A
IL262482A IL262482A IL26248218A IL262482A IL 262482 A IL262482 A IL 262482A IL 262482 A IL262482 A IL 262482A IL 26248218 A IL26248218 A IL 26248218A IL 262482 A IL262482 A IL 262482A
Authority
IL
Israel
Prior art keywords
novel polypeptides
polypeptides
novel
Prior art date
Application number
IL262482A
Other languages
English (en)
Hebrew (he)
Inventor
Eva Dahlen
Peter Ellmark
Christina Furebring
Per Norlen
Anna Sall
Laura Von Schantz
Niina Veitonmaki
Sara Fritzell
Jessica Petersson
Laura Varas
Original Assignee
Alligator Bioscience Ab
Eva Dahlen
Peter Ellmark
Christina Furebring
Per Norlen
Anna Sall
Laura Von Schantz
Niina Veitonmaki
Sara Fritzell
Jessica Petersson
Laura Varas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alligator Bioscience Ab, Eva Dahlen, Peter Ellmark, Christina Furebring, Per Norlen, Anna Sall, Laura Von Schantz, Niina Veitonmaki, Sara Fritzell, Jessica Petersson, Laura Varas filed Critical Alligator Bioscience Ab
Publication of IL262482A publication Critical patent/IL262482A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
IL262482A 2016-04-22 2018-10-21 New polypeptides IL262482A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201607046 2016-04-22
PCT/EP2017/059656 WO2017182672A1 (fr) 2016-04-22 2017-04-24 Nouveaux polypeptides bispécifiques dirigés contre le cd137

Publications (1)

Publication Number Publication Date
IL262482A true IL262482A (en) 2018-12-31

Family

ID=58609424

Family Applications (1)

Application Number Title Priority Date Filing Date
IL262482A IL262482A (en) 2016-04-22 2018-10-21 New polypeptides

Country Status (14)

Country Link
US (2) US20190169308A1 (fr)
EP (1) EP3445788B1 (fr)
JP (2) JP2019523630A (fr)
KR (1) KR102426765B1 (fr)
CN (1) CN109195994A (fr)
AU (1) AU2017252233A1 (fr)
BR (1) BR112018071612A2 (fr)
CA (1) CA3021618A1 (fr)
DK (1) DK3445788T3 (fr)
ES (1) ES2910365T3 (fr)
IL (1) IL262482A (fr)
MX (1) MX2018012897A (fr)
RU (1) RU2018139339A (fr)
WO (1) WO2017182672A1 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3464367B1 (fr) 2016-05-27 2020-09-09 AbbVie Biotherapeutics Inc. Protéines de liaison bispécifiques se liant à une protéine immunomodulatrice et à un antigène tumoral
BR112018076519A8 (pt) 2016-06-20 2022-07-12 F Star Delta Ltd Moléculas de ligação que se ligam a pd-l1 e lag-3
BR112018076525A2 (pt) 2016-06-20 2019-04-02 F-Star Beta Limited membros de ligação a lag-3
CN109641959B (zh) 2016-07-14 2023-08-22 健玛保 针对cd40和cd137的多特异性抗体
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
BR112019005895A2 (pt) * 2016-09-23 2019-06-11 Merus N.V. moléculas de ligação que modulam uma atividade biológica expressa por uma célula
EP3619235A1 (fr) 2017-04-11 2020-03-11 Inhibrx, Inc. Constructions polypeptidiques multispécifiques comprenant une liaison cd3 contrainte et leurs méthodes d'utilisation
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc anticorpos anti-cd137 e métodos de uso dos mesmos
CN111148763B (zh) * 2017-07-20 2023-11-03 Aptevo研究与开发公司 结合于5t4和4-1bb的抗原结合蛋白以及相关组合物和方法
MX2020001198A (es) 2017-08-04 2020-09-07 Genmab As Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos.
KR20200083574A (ko) * 2017-11-13 2020-07-08 크레센도 바이오로직스 리미티드 Cd137 및 psma에 결합하는 분자
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
AU2018387741A1 (en) 2017-12-19 2020-07-23 F-Star Therapeutics Limited FC binding fragments comprising a PD-L1 antigen-binding site
CN109970865B (zh) * 2017-12-28 2022-10-04 上海细胞治疗研究院 一种cd137双向激活共刺激分子受体及其用途
MA52152A (fr) * 2018-03-12 2021-01-20 Genmab As Anticorps
AU2019247795A1 (en) * 2018-04-04 2020-11-12 Bicycletx Limited Heterotandem bicyclic peptide complexes
US20210198370A1 (en) * 2018-05-31 2021-07-01 Board Of Regents, The University Of Texas System Bi-specific antibodies and use thereof
JP2021525537A (ja) * 2018-06-06 2021-09-27 レアダルティス、ソシエダッド リミターダＬｅａｄａｒｔｉｓ， Ｓ．Ｌ． 三量体ポリペプチド複合体およびその使用
US11180531B2 (en) * 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811450D0 (en) * 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811415D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
MX2021004058A (es) * 2018-10-10 2021-06-04 Zymeworks Inc Construcciones de anticuerpos que se unen a 4-1bb y a antigenos asociados a tumores y sus usos.
TW202021986A (zh) * 2018-10-11 2020-06-16 美商英伊布里克斯公司 5t4單域抗體及其治療性組合物
US20210403575A1 (en) * 2018-10-22 2021-12-30 Shanghai Yichen Biomed Co. Ltd Bispecific antibody
JP7328658B2 (ja) * 2018-11-30 2023-08-17 エービーエル バイオ インコーポレイテッド 抗ｐｄ－ｌ１／抗４－１ｂｂ二重特異性抗体およびその使用
WO2020127376A2 (fr) * 2018-12-17 2020-06-25 Alligator Bioscience Ab Nouveaux polypeptides
CN113677710A (zh) * 2018-12-17 2021-11-19 鳄鱼生物科学公司 多肽
TWI793395B (zh) * 2019-01-25 2023-02-21 大陸商信達生物製藥（蘇州）有限公司 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體
GB201905100D0 (en) * 2019-04-10 2019-05-22 Antibody Innovation Ltd Polypeptides and methods of use
MX2021013669A (es) 2019-05-09 2021-12-10 Bicycletx Ltd Ligandos peptidicos biciclicos especificos para ox40.
AU2020320349A1 (en) * 2019-07-26 2022-02-17 Abl Bio Inc. Anti-EGFR/anti-4-1BB bispecific antibody and use thereof
AU2020320233A1 (en) * 2019-07-26 2022-02-17 Yuhan Corporation Anti-HER2/anti-4-1BB bispecific antibody and use thereof
TW202110485A (zh) 2019-07-30 2021-03-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN112592404B (zh) * 2019-09-20 2023-07-25 上海交通大学医学院 抗体活性改造及其筛选方法
JP2022551607A (ja) * 2019-10-03 2022-12-12 バイスクルテクス・リミテッド ヘテロタンデム二環式ペプチド複合体
EP3816185A1 (fr) 2019-11-04 2021-05-05 Numab Therapeutics AG Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur
WO2021101346A1 (fr) * 2019-11-21 2021-05-27 Dong-A St Co., Ltd. Anticorps bispécifiques anti-ror1/anti-4-1bb et leurs utilisations
US20230048361A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
WO2021137231A1 (fr) 2019-12-31 2021-07-08 Kahr Medical Ltd. Procédés de culture de lymphocytes t avec un polypeptide de fusion 4-1bbl et leurs utilisations
BR112022012918A2 (pt) 2020-01-07 2022-09-06 Univ Texas Variantes de enzima de exaustão de metiltioadenosina/adenosina humana melhorada para terapia do câncer
CN115151573A (zh) * 2020-02-28 2022-10-04 上海复宏汉霖生物技术股份有限公司 抗cd137构建体、多特异性抗体及其用途
CA3146977A1 (fr) * 2020-04-15 2021-10-21 Zymeworks Inc. Constructions d'anticorps se liant a 4-1bb et recepteurs alpha de folate et leurs utilisations
KR20230042524A (ko) * 2020-08-07 2023-03-28 주식회사 유틸렉스 항-her2 / 항-4-1bb 이중특이적 항체 및 이의 용도
JP2023547507A (ja) * 2020-11-03 2023-11-10 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 標的細胞限定的で共刺激性の二重特異性かつ２価の抗ｃｄ２８抗体
EP4281467A1 (fr) * 2021-01-25 2023-11-29 Yuhan Corporation Procédés de purification d'un anticorps bispécifique anti-4-1bb / anti-her2
AU2022340645A1 (en) * 2021-09-02 2024-02-29 Memorial Hospital For Cancer And Allied Diseases Anti-cd33 antibodies and uses thereof
CA3233994A1 (fr) * 2021-10-12 2023-04-20 Wenci GONG Anticorps anti-4-1bb a domaine unique
WO2023174521A1 (fr) * 2022-03-15 2023-09-21 Genmab A/S Agents de liaison se liant à epcam et cd137
WO2024051752A1 (fr) * 2022-09-06 2024-03-14 I-Mab Biopharma Co., Ltd. Constructions multispécifiques et leurs utilisations
WO2024061364A1 (fr) * 2022-09-22 2024-03-28 成都盛世君联生物技术有限公司 Nanocorps anti-4-1bb, sa préparation et son utilisation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (fr) 1995-12-15 2008-10-14 Nobuyuki Takechi Production de microsphere
KR20020049054A (ko) * 1999-11-18 2002-06-24 찰스 굿맨 항체
WO2001056603A1 (fr) * 2000-02-01 2001-08-09 Tanox, Inc. Molecules d'activation des apc se liant au cd40
PA8645301A1 (es) 2004-09-10 2006-07-03 Wyeth Corp Anticuerpo anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
CN103347898B (zh) * 2011-01-10 2017-12-05 Ct大西洋有限公司 包括与肿瘤相关抗原结合抗体的联合治疗
PT2691417T (pt) 2011-03-29 2018-10-31 Roche Glycart Ag Variantes de fc de anticorpos
WO2013041687A1 (fr) * 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Molécules de liaison bispécifiques pour 5t4 et cd3
EP2948475A2 (fr) * 2013-01-23 2015-12-02 AbbVie Inc. Procédés et compositions pour la modulation du systéme immunitaire
ES2900898T3 (es) * 2014-04-07 2022-03-18 Chugai Pharmaceutical Co Ltd Anticuerpos biespecíficos inmunoactivadores
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
CN105233291A (zh) * 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CA3224830A1 (fr) * 2015-01-08 2016-07-14 Biontech Ag Agents agonistes se liant aux recepteurs du tnf
EP3245227A4 (fr) * 2015-01-14 2018-07-25 Compass Therapeutics LLC Constructions de liaison à des antigènes immunomodulateurs multispécifiques
WO2016185016A1 (fr) * 2015-05-21 2016-11-24 Alligator Bioscience Ab Nouveaux polypeptides
US11459394B2 (en) * 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof

Also Published As

Publication number Publication date
CN109195994A (zh) 2019-01-11
DK3445788T3 (en) 2022-04-11
RU2018139339A (ru) 2020-05-22
EP3445788A1 (fr) 2019-02-27
CA3021618A1 (fr) 2017-10-26
KR102426765B1 (ko) 2022-07-29
JP2022058338A (ja) 2022-04-12
US20220213213A1 (en) 2022-07-07
EP3445788B1 (fr) 2022-01-19
AU2017252233A1 (en) 2018-11-15
RU2018139339A3 (fr) 2020-09-28
BR112018071612A2 (pt) 2019-02-19
ES2910365T3 (es) 2022-05-12
JP2019523630A (ja) 2019-08-29
MX2018012897A (es) 2019-01-17
US20190169308A1 (en) 2019-06-06
WO2017182672A1 (fr) 2017-10-26
KR20180135454A (ko) 2018-12-20

Similar Documents

Publication Publication Date Title
IL262482A (en) New polypeptides
IL255767A (en) New polypeptides
ZA201802261B (en) Polypeptides
HK1250041A1 (zh) 多肽
GB201611530D0 (en) Novel polypeptides
HK1254601A1 (zh) 新型肽
ZA201704366B (en) Il-17a-binding polypeptides
HK1250040A1 (zh) 多肽
GB201608197D0 (en) Novel proteins
ZA201701348B (en) New polypeptides
GB201607534D0 (en) Peptides
GB201707139D0 (en) Polypeptides
GB201619652D0 (en) Novel polypeptides
GB201604468D0 (en) Peptides
GB201607535D0 (en) Peptides
IL246533A0 (en) new proteins
GB201717958D0 (en) Novel polypeptides
GB201706915D0 (en) Novel polypeptides
GB201515245D0 (en) Novel polypeptides
GB201620022D0 (en) Novel peptide
GB201622143D0 (en) Modification of polypeptides
GB201612665D0 (en) Peptides
GB201608820D0 (en) Peptides
GB201603582D0 (en) Peptides
GB201419237D0 (en) Novel polypeptides